15066065

Source:http://linkedlifedata.com/resource/pubmed/id/15066065

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0019557, umls-concept:C0030705, umls-concept:C0442027, umls-concept:C0528358, umls-concept:C1280500, umls-concept:C2697525
pubmed:issue	4
pubmed:dateCreated	2004-4-6
pubmed:abstractText	To evaluate the effects of MK-0677, an orally active growth hormone (GH) secretagogue, on functional recovery from hip fracture in previously mobile older individuals.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7503062
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Glucose, http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobin A, Glycosylated, http://linkedlifedata.com/resource/pubmed/chemical/Indoles, http://linkedlifedata.com/resource/pubmed/chemical/Insulin, http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor I, http://linkedlifedata.com/resource/pubmed/chemical/L 163191, http://linkedlifedata.com/resource/pubmed/chemical/Spiro Compounds
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	0002-8614
pubmed:author	pubmed-author:BachMark AMA, pubmed-author:BeisawNormanN, pubmed-author:ChristiansenJens SandahlJS, pubmed-author:DevogelaerJean-PierreJP, pubmed-author:FarringtonJeanneJ, pubmed-author:FuhVivianV, pubmed-author:GluckOscarO, pubmed-author:HébertRéjeanR, pubmed-author:MK 0677 Hip Fracture Study Group, pubmed-author:NgJenniferJ, pubmed-author:OchsnerJ LockwoodJL, pubmed-author:RizzoliRenéR, pubmed-author:RockwoodKennethK, pubmed-author:SchwabThomasT, pubmed-author:TaylorAlice MAM, pubmed-author:ThamsborgGormG, pubmed-author:YuLeisureL, pubmed-author:ZetterbergCarlC
pubmed:issnType	Print
pubmed:volume	52
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	516-23
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:15066065-Activities of Daily Living, pubmed-meshheading:15066065-Administration, Oral, pubmed-meshheading:15066065-Aged, pubmed-meshheading:15066065-Double-Blind Method, pubmed-meshheading:15066065-Female, pubmed-meshheading:15066065-Geriatric Assessment, pubmed-meshheading:15066065-Glucose, pubmed-meshheading:15066065-Hemoglobin A, Glycosylated, pubmed-meshheading:15066065-Hip Fractures, pubmed-meshheading:15066065-Humans, pubmed-meshheading:15066065-Indoles, pubmed-meshheading:15066065-Insulin, pubmed-meshheading:15066065-Insulin-Like Growth Factor I, pubmed-meshheading:15066065-Longitudinal Studies, pubmed-meshheading:15066065-Male, pubmed-meshheading:15066065-Mental Competency, pubmed-meshheading:15066065-Questionnaires, pubmed-meshheading:15066065-Recovery of Function, pubmed-meshheading:15066065-Safety, pubmed-meshheading:15066065-Sickness Impact Profile, pubmed-meshheading:15066065-Spiro Compounds, pubmed-meshheading:15066065-Treatment Outcome
pubmed:year	2004
pubmed:articleTitle	The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture.
pubmed:affiliation	Merck Research Laboratories, Rahway, New Jersey, USA.
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study